Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies
I Altintas, RJ Kok, RM Schiffelers - European journal of pharmaceutical …, 2012 - Elsevier
The discovery of naturally occurring heavy chain only antibodies and their further
development into small recombinant 'nanobodies' offers attractive applications in drug …
development into small recombinant 'nanobodies' offers attractive applications in drug …
Therapeutic human monoclonal antibodies against cancer
J Jarboe, A Gupta, MW Saif - Human Monoclonal Antibodies: Methods and …, 2014 - Springer
There are over 30 monoclonal antibodies that are FDA approved for a variety of diseases
ranging from malignancies to autoimmune diseases to macular degeneration. These …
ranging from malignancies to autoimmune diseases to macular degeneration. These …
[HTML][HTML] Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines
R Nagel, SR Martens-de Kemp, M Buijze, G Jacobs… - Oral oncology, 2013 - Elsevier
OBJECTIVES: Infection with the human papillomavirus (HPV) is an important risk factor for
development of head and neck squamous cell carcinoma (HNSCC). Strikingly, HPV-positive …
development of head and neck squamous cell carcinoma (HNSCC). Strikingly, HPV-positive …
Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors
A Lowery, H Onishko, DE Hallahan, Z Han - Journal of controlled release, 2011 - Elsevier
Tumor-targeted drug delivery improves anti-tumor efficacy and reduces systemic toxicity by
limiting bioavailability of cytotoxic drugs to within tumors. Targeting reagents, such as …
limiting bioavailability of cytotoxic drugs to within tumors. Targeting reagents, such as …
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic …
D Strumberg, B Schultheis, ME Scheulen… - Investigational new …, 2012 - Springer
Introduction Nimotuzumab is a humanized monoclonal antibody that binds to the EGFR.
Based on phase I data, the recommended dose has been established at 200 mg weekly …
Based on phase I data, the recommended dose has been established at 200 mg weekly …
[HTML][HTML] Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin‑resistant oral cancer CAR cells through intrinsic apoptotic process
CF Chen, CC Lu, JH Chiang, HY Chiu… - Oncology …, 2018 - spandidos-publications.com
Cetuximab, an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody
(mAb), is a novel targeted therapy for the treatment of patients with oral cancer. Cetuximab …
(mAb), is a novel targeted therapy for the treatment of patients with oral cancer. Cetuximab …
[HTML][HTML] The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement …
R Kesselring, A Thiel, R Pries, S Fichtner-Feigl… - European Journal of …, 2014 - Elsevier
Background Membrane-bound complement restriction proteins (mCRPs) CD46, CD55 and
CD59 enable tumour cells to evade complement dependent cytotoxicity and antibody …
CD59 enable tumour cells to evade complement dependent cytotoxicity and antibody …
Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study
Purpose: To assess the pharmacodynamic effects of nimotuzumab, an anti–epidermal
growth factor receptor (EGFR) monoclonal antibody with intermediate affinity for the …
growth factor receptor (EGFR) monoclonal antibody with intermediate affinity for the …
Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III
J Fukai, K Nishio, T Itakura, F Koizumi - Cancer science, 2008 - Wiley Online Library
Anti‐epidermal growth factor receptor (EGFR) monoclonal antibody, cetuximab, is a
promising targeted drug for EGFR‐expressing tumors. Glioblastomas frequently overexpress …
promising targeted drug for EGFR‐expressing tumors. Glioblastomas frequently overexpress …
[HTML][HTML] Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma
AG Wernicke, AP Dicker, M Whiton, J Ivanidze… - Radiation …, 2010 - Springer
Purpose This study explores whether meningioma expresses epidermal growth factor
receptor (EGFR) and determines if there is a correlation between the WHO grade of this …
receptor (EGFR) and determines if there is a correlation between the WHO grade of this …